Tri-modal Imaging Instrument for Thyroid Cancer
- Conditions
- Thyroid NeoplasmsThyroid CancerThyroid Nodule
- Interventions
- Device: Tri-modal imaging
- Registration Number
- NCT02758158
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
Thyroid cancer affects 6,000 Canadians each year. Nodules on the thyroid are detected using ultrasound imaging and surgery is the most common treatment. However, most nodules are benign, and therefore a biopsy is needed to decide whether surgery is necessary. Ultrasound imaging is very sensitive for localizing nodules, but does not differentiate between cancerous and benign ones. To address this limitation of US imaging, investigators have designed and constructed, in collaboration with Sogang University, Seoul, S. Korea, a novel imaging system that performs complimentary imaging modalities (ultrasound (US), photoacoustic (PA)) that could potentially help diagnose nodules without the need for biopsy and unnecessary surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
- Male or female patients with thyroid nodules (cancerous, benign or undetermined)
- 18 years of age or older
- Have been consented to their standard-of-care surgery for resection of the thyroid (partial or complete) and lymph nodes (if applicable)
- Have had pre-surgical US imaging of the thyroid and lymph nodes
- Inability to provide informed consent
- Pre-operative therapy for current thyroid cancer (including chemotherapy, endocrine therapy and radiotherapy)
- History of photosensitivity or skin disease (exposure to laser light is involved in PA imaging)
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Tri-modal imaging Tri-modal imaging Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
- Primary Outcome Measures
Name Time Method Detect/localize thyroid nodules and lymph nodes in vivo by using tri-modal imaging up to 5 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada